Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia
Deep, durable, and consistent median triglyceride reductions of 79% and 81% from baseline in SHASTA...
Publisher
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Arrowhead Pharmaceuticals
- Region
- USA
- Scope
- Industry
- Published
- July 22, 2026
- Language
- EN
Topics
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
Deep, durable, and consistent median triglyceride reductions of 79% and 81% from baseline in SHASTA...
Source route
Continue on arrowheadpharma.com
Leave the platform to read the original full article on the publisher site.
Source: Arrowhead Pharmaceuticals
Scope: Industry
Related coverage
More related coverage
More details
NS-025の全世界における開発・製造・販売に関する独占的ライセンス契約締結のお知らせ
Lilly confirms date and conference call for second-quarter 2026 financial results announcement
INDIANAPOLIS, July 22, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its seco...